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Lately, when researchers see an article with the word
‘‘biomarker’’, they feel, at least, suspicious. Sometimes,
even scared and such feeling of distrust occurs mostly
because the majority of the published articles in the ﬁeld of
global proteome analysis are revealing, for instance, dif-
ferentially expressed proteins in pathologic conditions and
claiming that biomarkers are being discovered. In addition
to transform a differentially expressed protein in a bio-
marker, a long road has to be travelled.
Biomarker is deﬁned by the United States Food and
Drug Administration (FDA) as ‘‘a characteristic that is
objectively measured and evaluated as an indicator of
normal biologic or pathogenic processes or pharmacolog-
ical responses to a therapeutic intervention’’ [1]. Such
deﬁnition is, indeed, quite speciﬁc and very different from
a differentially expressed protein discovered as potentially
related to some disease in a small set of sample. Therefore,
researchers are totally correct regarding their suspicions.
Searching at PubMed database (31 Dec 2009), the word
‘‘biomarker’’ returns 477,273 different articles that have
exponentially increased in the recent years (Fig. 1a). If the
words ‘‘biomarker and proteomics (or proteome)’’ are
searched, we can also realize a massive number of articles
in the past 13 years (30,719 articles), and an exponential
increase in the number of lately published articles
(Fig. 1b). Searching the word ‘‘biomarker’’ from 1996 to
2009 (1996 was when the ﬁrst article of proteomics (or
proteome) and biomarker was published), we can ﬁnd
342,751 articles, which means that proteomics research
have published 8.96% of the articles which contains
‘‘biomarker’’ as keyword. This huge number of articles is
very far to be at same proportion to the number of the
recently discovered biomarkers that are useful to disease
diagnosis, indicators of disease status, or targets to monitor
and predict response to therapeutics or disease outcome
and such data show us that a better deﬁnition for differ-
entially expressed proteins with potential to be biomarkers
has to be implemented, to leave the word ‘‘biomarker’’ to
its own and well-deﬁned meaning, avoiding the misuse of
the term.
Recently, researchers have been used safer terms such as
‘‘potential biomarker’’ or ‘‘biomarker candidate’’ for pro-
teins differentially expressed in diseased conditions that
might have a potential as biomarker. I would propose that
the correct term for most of developed research regarding
biomarker discover based on the most of published articles
not only for proteomics, but also in transcriptome and
association studies, would be ‘‘potential biomarker candi-
date’’ (PBC). Why such name? Considering a differential
proteome analysis comparing healthy and diseased tissue,
differentially expressed protein will be found by high
throughput and semi-automatic proteomics methods. At
this point, I would say we would have a simple ‘‘biomarker
candidate’’, which means something far, at least two levels
away from a real biomarker. The biomarker candidates
need to be validated in a greater and statistically signiﬁcant
universe of individual samples using distinct methodolo-
gies such as Western blot, ELISA or single and multiple
reaction monitoring (SRM or MRM). If such proteins are
indeed validated as differentially expressed, then we would
have a second level of candidate, which I would call PBC.
And we are clearly aware that for a PBC reach the
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using different parameters and technologies, studying dif-
ferent sets of samples, considering potential confounding
factors. A good review for that can be found at Mischak
et al. [2] and its references.
Sets of adequate standards to proteomics studies for
biomarker discovery have been already proposed, applied
in proteome research [2] and required by proteomics
journals. Now, we need to deﬁne to ‘‘potential biomarkers’’
or ‘‘biomarker candidates’’ a better and clearer term or
name that could really be distinct from ‘‘biomarker’’, that
has its own and well-deﬁned meaning. For most of clinical
proteomics studies, I believe that PBC would be a con-
siderable suggestion. This way, it would be possible to
clearly separate PBC from biomarker, two entities that
have very different concepts and distinct values. Moreover,
an adequate nomenclature would facilitate the judgment of
the researchers and reviewers, who may feel more com-
fortable to read PBC instead biomarker in clinical proteo-
mics studies.
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